Research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-20 and is reviewed periodically as new material appears.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Portugal has contributed to the popularity and globalisation of sport through internationally recognised athletes such as Cristiano Ronaldo, Ricardinho, Naide Gomes, and Carlos Lopes, as well as through the popularity of its three largest football clubs. Football is the most popular sport in Portugal. The Portugal men's national football team won the UEFA European Championship in 2016 and the UEFA Nations League in 2019 and 2025. Portugal is among the world's leading futsal countries, with its men's national team having won the FIFA Futsal World Cup in 2021, the UEFA Futsal Championship in 2018 and 2022, and the Futsal Finalissima in 2022. In athletics, the country has set several records and has earned more medals in this sport than in any other at both the Olympic and Paralympic Games. In traditional sport, Portugal is noted for its classical dressage as well as native sports such as jogo do pau and jogo da malha. Portugal has several established sporting centres across the country, including the Algarve and Lisbon, which are international golf destinations and have hosted motorsport events such as Formula One and Grand Prix motorcycle racing, as well as Nazaré and Peniche, which are known for surfing and annually host the TUDOR Nazaré Big Wave Challenge and the MEO Rip Curl Pro Portugal, respectively.
==== Neurotrophic activity ==== Honokiol has been shown to promote neurite outgrowth and have neuroprotective effects in rat cortical neurons. Additionally, honokiol increases free cytoplasmic reforforason Ca2+ in rat cortical neurons. Honokiol is a weak CB2 receptor ligand but the naturally occurring derivative 4-O-methylhonokiol was shown to be a potent and selective cannabinoid CB2 receptor inverse agonist and to possess antiosteoclastic effects.
=== Pharmacodynamics === ETH-LAD acts as a serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It shows greater potency and efficacy as a serotonin 5-HT2A receptor agonist than LSD in vitro. In addition to the serotonin 5-HT2A receptor, the drug binds with high affinity to the serotonin 5-HT1A and 5-HT2C receptors. Like LSD, ETH-LAD also binds with lower affinity to the dopamine D1, D2, D3, D4, and D5 receptors. ETH-LAD shows psychedelic-like effects in animals, specifically rodent drug discrimination tests. It is about 1.6- to 2.3-fold more potent than LSD in these tests. Similarly to LSD, ETH-LAD shows moderate anti-inflammatory effects in preclinical research, but with slightly higher potency.
== Naturally occurring stable nuclides == As noted, this number is about 251. For a list, see the article list of elements by stability of isotopes. For a complete list noting which of the "stable" 251 nuclides may be in some respect unstable, see list of nuclides and stable nuclide. These questions do not impact the question of whether a nuclide is primordial, since all "nearly stable" nuclides, with half-lives longer than the age of the universe, are also primordial.
Sources: en.wikipedia.org
== External links == "Do insects have blood?". Boston Globe. October 17, 2005. Archived from the original on October 2, 2022. Bolstad, Kat (May 2, 2008). "Blue Squid Blood - Murky Water". Te Papa Tongarewa Museum of New Zealand. Archived from the original on April 2, 2015.
A few P-51 Mustangs were illegally bought by Israel in 1948, crated, and smuggled into the country as agricultural equipment for use in the 1947–1949 Palestine war, serving alongside upwards of 23 Avia S-199 fighters (Czech-built Messerschmitt Bf 109Gs) in Israeli service, with the Mustangs quickly establishing themselves as the best fighter in the Israeli inventory. Further aircraft were bought from Sweden and were replaced by jets at the end of the 1950s, but not before the type was used in the Suez Crisis, at the opening of Operation Kadesh. In conjunction with a surprise parachute drop at the Mitla Pass, four P-51s were specially detailed to cut telephone and telegraph wires using their wings in extreme low level runs, which resulted in major interruptions to Egyptian communications. Italy
== Research == With his team in the Ciulli laboratory, Ciulli's works aim to develop small molecules inducing targeted protein degradation and modulating protein-protein interactions. One example of this type of work is the discovery of proteolysis-targeting chimera or PROTAC and its therapeutic potential. Recruitment of an E3 ligase to the target protein by the PROTAC is a critical step in the mechanism of action, because it triggers the target protein to be ubiquitinated and then degraded by the proteasome. Ciulli and his colleagues were the first to produce an X-ray crystal structure of a class of PROTAC simultaneously bound to the target protein and the E3 ubiquitin ligase. Much of Ciulli's research also contributed to studies on the Von Hippel-Lindau protein E3 ligase, especially in targeting the E3 ligase with small molecules. In general, Ciulli's scientific contributions focus on targeted protein degradation (TPD) as a therapeutic modality in cancer and other diseases. His works on TPD led to the founding of Amphista Therapeutics. Amongst the other scientific accomplishments and discoveries of his laboratory, is the development of a chemical-genetic "bump and hole" approach in which Ciulli and colleagues designed an engineered mutant variant of BET bromodomains able to accommodate selectively its binding ligand, enabling the individual roles of BET proteins to be elucidated.
There are many cultivars of blackcurrant. 'Baldwin' was the mainstay of the industry for many years but it has now largely been superseded by more productive and disease-resistant varieties. During the 20th century in Europe, much hybridisation work has been carried out in order to reduce the plant's susceptibility to disease and frost and also to increase yields. This effort centered mainly in Scotland, Poland, and New Zealand. In Britain the Scottish Crop Research Institute was tasked with developing new varieties suitable for growing in the north of the country. They produced new cultivars that had greater cold tolerance, especially in the spring, ripened earlier and more evenly and had greater fungal disease resistance. Frost tolerance was improved by selecting for late flowering and genetic research identified genes involved in resistance to gall mite and the blackcurrant reversion virus. 'Ben Lomond' was the first of the 'Ben' varieties and was released in 1975. This was followed by several other cultivars for the juicing industry such as 'Ben Alder' and 'Ben Tirran'. The cultivar 'Ben Hope' was released in 1998 with increased tolerance to gall mite, and in the same year, 'Ben Gairn' became available. It shows resistance to the reversion virus. For gardeners and the pick-your-own market, 'Ben Sarek', 'Ben Connan' and 'Big Ben' were introduced and have large, sweet berries. The cultivars 'Ben Connan' and 'Big Ben' have gained the Royal Horticultural Society's Award of Garden Merit.
A post hoc analysis of the IDEAL and the EPIC prospective studies found an association between high levels of HDL cholesterol (adjusted for apolipoprotein A-I and apolipoprotein B) and increased risk of cardiovascular disease, casting doubt on the cardioprotective role of "good cholesterol". About one in 250 individuals has a genetic mutation for the LDL cholesterol receptor that causes them to have familial hypercholesterolemia. Inherited high cholesterol can also include genetic mutations in the PCSK9 gene and the gene for apolipoprotein B. Elevated cholesterol levels are treatable by a diet that reduces or eliminates saturated fat, and trans fats, often followed by one of various hypolipidemic agents, such as statins, fibrates, cholesterol absorption inhibitors, monoclonal antibody therapy (PCSK9 inhibitors), nicotinic acid derivatives or bile acid sequestrants. There are several international guidelines on the treatment of hypercholesterolemia. Human trials using HMG-CoA reductase inhibitors, commonly known as statins, have repeatedly confirmed that changing lipoprotein transport patterns from unhealthy to healthier patterns significantly lowers cardiovascular disease event rates, even for people with cholesterol values currently considered low for adults. Studies have shown that reducing LDL cholesterol levels by about 38.7 mg/dL with the use of statins can reduce cardiovascular disease and stroke risk by about 21%. Studies have also found that statins reduce atheroma progression.
Sources: en.wikipedia.org
a sequence of elements of the pattern notation matches a sequence of amino acids if and only if the latter sequence can be partitioned into subsequences in such a way that each pattern element matches the corresponding subsequence in turn. Thus the pattern [AB] [CDE] F matches the six amino acid sequences corresponding to ACF, ADF, AEF, BCF, BDF, and BEF. Different pattern description notations have other ways of forming pattern elements. One of these notations is the PROSITE notation, described in the following subsection.
Although for the rest of his career Heseltine's role in Thatcher's downfall earned him enmity from Thatcher's supporters in the Conservative party, this opprobrium was not universal. In a reference to the reluctance of the Cabinet to support Thatcher on the second ballot, Edward Leigh said of Heseltine: "At least he stabbed her in the front". Heseltine believed that he would have defeated Thatcher if she had contested the second ballot. It has been suggested that he should have withdrawn after weakening her on the first ballot, and that he would have been restored to the Cabinet whether or not she continued as prime minister; he writes that this was never seriously suggested at the time.
The mechanism of this sub-type of muscular dystrophy consists of a mutation in the FKTN gene which results in a malformed fukutin protein. It is thought that fukutin modifies the alpha-dystroglycan protein, which is important in anchoring cells to certain molecules, specifically including some proteins. Alpha-dystroglycan in skeletal muscles helps to prevent the breakdown of muscle fibers through stabilization and protection. Alpha-dystroglycan also helps brain development by assisting in the migration of neurons. Most frequently, FKTN is mutated in such a way that creates a shortage of fukutin in the cell, which in turn creates problems during formation of alpha-dystroglycan leading to less stabilization of muscle cells. Use of the destabilized muscle fibers over time causes them to break down and a gradual decline in muscle tone and atrophy of muscle fibers occurs. The decline in cerebral fukutin causes neuronal cells to continue moving beyond their intended destination. Additionally, oxidative stress has some effect on astrocytes (as well as, neurons) when fukutin is subdued.
=== Flow: Sverdrup === One sverdrup (Sv) is equal to 1,000,000 cubic metres per second (264,000,000 USgal/s). It is used almost exclusively in oceanography to measure the volumetric rate of transport of ocean currents.
=== Tracking selection progression === To track the progress of a SELEX reaction, the number of target bound molecules, which is equivalent to the number of oligonucleotides eluted, can be compared to the estimated total input of oligonucleotides following elution at each round. The number of eluted oligonucleotides can be estimated through elution concentration estimations via 260 nm wavelength absorbance or fluorescent labeling of oligonucleotides. As the SELEX reaction approaches completion, the fraction of the oligonucleotide library that binds target approaches 100%, such that the number of eluted molecules approaches the total oligonucleotide input estimate, but may converge at a lower number.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.